Ramucirumab Plus FOLFIRI as Second-Line Therapy for RAS Wild-Type Metastatic Colorectal Cancer Previously Treated With an Anti-EGFR Antibody
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16
ESMO Open 2023 Oct 01;8(5)101636, H Yasui, Y Okita, M Nakamura, T Sagawa, T Watanabe, K Kataoka, D Manaka, K Shiraishi, N Akazawa, T Okuno, T Shimura, M Shiozawa, Y Sunakawa, H Ota, M Kotaka, H Okuyama, M Takeuchi, W Ichikawa, M Fujii, A TsujiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.